General Information of Drug (ID: DM1MZAQ)

Drug Name
Zilovertamab vedotin Drug Info
Synonyms MK-2140
Indication
Disease Entry ICD 11 Status REF
Diffuse large B-cell lymphoma 2A81 Phase 2/3 [1]
Cross-matching ID
TTD Drug ID
DM1MZAQ

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cirmtuzumab DM98RW0 Chronic lymphocytic leukaemia 2A82.0 Phase 2 [3]
VLS-101 DMLT94F Solid tumour/cancer 2A00-2F9Z Phase 2 [4]
Zilovertamab DMMEJ6K Mantle cell lymphoma 2A85.5 Phase 2 [5]
NBE-002 DMTAODR Solid tumour/cancer 2A00-2F9Z Phase 1/2 [6]
ROR1R-CAR-T Cell DMIAK9P leukaemia 2A60-2B33 Phase 1 [7]
ROR1 CAR-specific Autologous T-Lymphocytes DM5EUIY Acute lymphoblastic leukaemia 2A85 Phase 1 [8]
⏷ Show the Full List of 6 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Neurotrophic tyrosine kinase ROR1 (ROR1) TTDEJAU ROR1_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT05139017) A Phase 2/3 Multicenter, Open-label, Randomized, Active-Control Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-003). U.S.National Institutes of Health.
2 ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models. Blood. 2021 Jun 17;137(24):3365-3377.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Clinical pipeline report, company report or official report of VelosBio.
5 The Anti-ROR1 Monoclonal Antibody Zilovertamab Inhibits the Proliferation of Ovarian and Endometrial Cancer Cells. Pharmaceutics. 2022 Apr 11;14(4):837.
6 Clinical pipeline report, company report or official report of NBE-Therapeutics.
7 ClinicalTrials.gov (NCT02194374) Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)
8 ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies